PTC Therapeutics: Hold Rating Amid Strategic Collaboration with Novartis and Clinical Uncertainties
Analyst Joseph Schwartz from Leerink Partners reiterated a Hold rating on PTC Therapeutics (PTCT – Research Report) and increased the price ...
pharmaphorum5d
Novartis pays $1bn upfront for Huntington's drug from PTC
Novartis has made a dramatic return to the Huntington's disease therapy stage by licensing a candidate from PTC Therapeutics for a whopping $1 billion upfront. The deal – which has a potential ...
Zacks.com on MSN2d
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
Novartis NVS announced positive top-line results from a late-stage study on Fabhalta (iptacopan) in adult patients with ...
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and ...
MM&M6d
Rx Rundown: Eli Lilly, Amgen, GSK and more
President-elect Donald Trump hosted the chief executives of Pfizer, Eli Lilly and PhRMA at Mar-a-Lago for a dinner with ...
pharmaphorum1d
uniQure rockets on map to market for Huntington's therapy
Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...
The Pharma Letter4d
The week in pharma: action, reaction and insight – week to December 6
Deal-making featured strongly among last week’s news, first with PCT Therapeutics inking an up to 2.9 billion collaboration ...